RxDoctor Payments Data

Stewart Chumbley

Family · Bozeman, MTNPI 1316351810

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,778 of the $5,325 with a category attached, or 89.7%. It is spread thinly across 34 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,325in general payments, 2019–2025

Across 165 payments — averaging $32.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$780
  • Teleflex LLC$720
  • Axonics, Inc.$623
  • Astellas Pharma US Inc$533
  • Boston Scientific$529
  • AbbVie$437
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$3356%
  • Food & beverage$4,77890%
  • Education$2124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,325 in reported general payments places this provider in the 95th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$108,280
Medicare patients
721
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron280$185,352
Tamsulosin Hcl626$10,569
Potassium Citrate ErPotassium Citrate58$5,527
Finasteride368$5,379
Mirabegron ErMirabegron15$5,308
Testosterone20$3,324
Solifenacin Succinate102$3,091
Tolterodine Tartrate ErTolterodine Tartrate40$1,996
Dutasteride63$1,835
Testosterone Cypionate41$1,775
Alfuzosin Hcl ErAlfuzosin Hcl88$1,699
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst99$1,326
Chlorthalidone74$964
CefuroximeCefuroxime Axetil30$351
Oxybutynin Chloride ErOxybutynin Chloride20$345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$533$185,352280 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 family providers in Montana.

Other family in Bozeman

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →